(AP) – Some key experimental drugs in late-stage testing by biopharmaceutical company Bristol-Myers Squibb Co.:
-ipilimumuab, for melanoma, the most dangerous type of skin cancer. Data from a late-stage study could be presented at a major cancer meeting in June; the company will soon seek regulatory approval for use in patients previously treated for the cancer. The company also will start a late-stage study of the drug for non-small cell lung cancer.
-apixiban, for preventing life-threatening blood clots. Bristol-Myers will seek approval in Europe by June and may see U.S. approval by year-end. It’s also testing the drug for preventing strokes.
-belatacept, for preventing rejection of a newly transplanted kidney. A panel of Food and Drug Administration advisers voted 13 to 5 on Monday to recommend approval, and the agency could rule by May 1. Approval also is pending in Europe.
-dapagliflozin, to control blood sugar and reduce weight and blood pressure in diabetics. The company may file for U.S. and European approval by year-end.
-brivanib, for liver cancer. It’s in late-stage testing.
-necitumumab, for non-small cell lung cancer. In late testing; being developed jointly with Eli Lilly & Co.
-XL-184, for brain tumors and other cancers. It’s also in late-stage testing.
Date: March 4, 2010
Source: Associated Press
Filed Under: Drug Discovery
